The protective effect of +45T >G polymorphism in the adiponectin gene (ADIPOQ) on coronary artery disease (CAD) has been demonstrated in European populations, so this study investigated the effect of +45T >G polymorphism on the risk of CAD and its interactions with other metabolic risk factors in a Chinese population. Methods and Results: The +45T >G polymorphism (rs2241766) of ADIPOQ was genotyped in 600 patients with angiographically diagnosed CAD and in 718 controls. The G allele at the +45T >G polymorphism was associated with a lower risk of CAD (odds ratio (OR), 0.76; 95% confidence interval (CI), 0.64-0.89; P=0.001). The protective effect of the G allele at +45T >G polymorphism was magnified at blood pressure <140/90 mmHg (OR, 0.65; 95%CI, 0.51-0.82; P=0.0004), but disappeared at blood pressure ≥140/90 mmHg (OR, 0.98; 95%CI, 0.76-1.28; P=0.93), indicating an interaction between +45T >G polymorphism and blood pressure on CAD risk (P=0.02 for interaction). A similar interaction was also observed between plasma cholesterol level and the +45T >G polymorphism. Conclusions: An association of ADIPOQ genetic polymorphism with CAD risk is modified by traditional risk factors, such as blood pressure and plasma cholesterol level. (Circ J 2009; 73: 1934 -1938 
diponectin, an adipocyte-secreted protein encoded by the ADIPOQ gene (Entrez Gene ID: 9370), exerts insulin-sensitizing and anti-atherogenic effects. 1,2 A prospective study found that plasma adiponectin concentration is associated with the risk of acute myocardial infarction independent of traditional cardiovascular risk factors. 3 Cross-sectional studies have also demonstrated a reverse relationship between the total or high-molecular weight form of adiponectin level and risk of coronary artery disease (CAD) or coronary events. [4] [5] [6] [7] [8] Adiponectin inhibits the progression of atherosclerosis in ApoE-deficient mice. 9 In adiponectin-deficient mice, severe neointimal thickening and proliferation of vascular smooth muscle cells has been observed in mechanically injured arteries while adenovirusmediated supplement of adiponectin attenuated neointimal proliferation. 10 These findings indicate a protective role of adiponectin in the progression of atherosclerosis.
The adiponectin gene consists of 3 exons and 2 introns spanning a 17-kb region 11 and has been located on chromosome 3q27, a genomic region linked with the insulin resistance trait. 12 Several common genetic variations of the human adiponectin gene have been reported. Among them, a single nucleotide polymorphism (SNP) +45T >G in exon 2 (rs2241766) of ADIPOQ has been extensively studied. 13, 14 The G allele at the +45T >G polymorphism has been associated with higher serum adiponectin concentrations, 15, 16 higher adiponectin mRNA expression in adipose tissue, 17 enhanced rosiglitazone reposne on serum adiponectin concentrations, 18, 19 improved insulin sensitivity, [20] [21] [22] and a lower risk of obesity. 17 Several studies also report a protective effect of the G allele at the +45T >G polymorphism on the risk of CAD in European populations. [23] [24] [25] However, no studies have investigated the effect of +45T >G polymorphism on the risk of CAD in a Chinese population, so we aimed to analyze this, as well as the interaction between various cardiovascular risk factors with +45T >G polymorphism on CAD risk. angiographically diagnosed CAD from the National Taiwan University Hospital. The diagnostic criterion for CAD was >75% stenosis of at least 1 segment of a major coronary artery found on coronary angiography performed because of clinical angina or abnormal resting ECG, or a documented history of transmural myocardial infarction. We also recruited 718 controls (383 men, 335 women) without a history of atherosclerotic vascular disease from the health check-up service of the hospital (275 participants) and a family cohort of Chinese origin (443 unrelated probands). 22 The study was approved by the institutional review board and each participant provided written informed consent before enrollment.
Demographic and Biochemical Measurements
We measured the body weight and height of participants while they wore light clothing and had bare feet. Blood pressure (BP) was measured using a mercury sphygmomanometer on 3 separate intervals. Blood was taken in the fasting state for measurements of plasma glucose, total cholesterol and triglyceride levels using an autoanalyzer (Hitachi 7250 Special, Tokyo, Japan).
DNA Extraction and Genotyping of +45T >G
Polymorphism of ADIPOQ Genomic DNA was prepared from frozen whole blood using a Puregene kit (Promega, Madison, NY, USA). The +45T >G polymorphism of ADIPOQ was genotyped using the polymerase chain reaction-restriction fragmented length polymorphism method as described previously. 17, 22 Statistical Analysis All data are expressed as mean ± standard deviation. Differences in continuous parameters, such as age, between the 2 groups were analyzed using Student's t-test. The allelic and genotypic association with CAD and OR estimation was analyzed using the chi-squared test with the TT genotype as the reference genotype. Univariate or multivariate logistic regression was used to estimate the unadjusted and adjusted association for other known CAD risk factors, including age, sex, body mass index (BMI), total cholesterol, triglyceride, BP, fasting plasma glucose, and current smoking. A P value <0.05 was considered statistically significant.
Results

Clinical Characteristics of Study Participants
The clinical characteristics of the study participants are shown in Table 1 . Participants with CAD were older and had higher BP, plasma total cholesterol, triglyceride, and fasting glucose levels than the controls. There were also more men and current smokers among the CAD cases.
Association of +45T >G Polymorphism of ADIPOQ With CAD and Other CAD Risk Factors
The genotype distribution of +45T >G polymorphism was within the Hardy-Weinberg equilibrium in both CAD cases and controls. The G allele at the +45T >G polymorphism was associated with a lower risk of CAD (odds ratio (OR), 0.76; 95% confidence interval (CI), 0.64-0.89; P=0.001; Table 2 ). The OR was 0.78 (95%CI, 0.61-0.98; P=0.03) for the GT genotype and 0.57 (95%CI, 0.37-0.86; P=0.005) for the GG genotype ( Table 2 ). The genetic model was best fit with an additive model. The G allele was associated with a trend of lower systolic BP (P=0.07), but was not associated with other metabolic phenotypes, including diastolic BP (P=0.22), BMI (P=0.90), fasting plasma glucose (P= 0.19), triglyceride (P=0.78), or total cholesterol (P=0.37) level in the control group. The association of the G allele with CAD was attenuated, but still significant, after adjustment for known CAD risk factors (adjusted OR, 0.75; 95%CI, 0.57-0.98; P=0.03; Table 3 ).
Interactions of +45T >G Polymorphism With Other CAD Risk Factors on CAD Risk
We next examined whether there was any interaction between the +45T >G polymorphism and traditional risk factors on the risk of CAD. An interaction between +45T >G polymorphism and BP was noted. The G allele was associated with a significantly lower risk of CAD in participants with BP <140/90 mmHg (OR, 0.65; 95%CI, 0.51-0.82; P=0.0004), but the protective effect disappeared in participants with BP ≥140/90 mmHg (OR, 0.98; 95%CI, 0.76-1.28; P=0.93), indicating an interaction between BP and +45T >G polymorphism on CAD risk (P=0.02 for interaction) (Figure B) .
A similar interaction was also found between plasma Table 1 . total cholesterol level and +45T >G polymorphism. The protective effect of the G allele was magnified in participants with a plasma total cholesterol level <200 mg/dl (OR, 0.68; 95%CI, 0.53-0.87; P=0.001), but disappeared when the total cholesterol level was ≥200 mg/dl (OR, 0.87; 95%CI, 0.68-1.13; P=0.29), indicating a interaction between ADIPOQ polymrophism and the plasma total cholesterol level on CAD risk (P=0.03 for interaction) (Figure A) . It is of note that the correlation between plasma cholesterol level and mean BP was weak in the present study (correlation coefficient, 0.06). There was no significant interaction between the +45T >G polymorphism and other CAD risk factors (data not shown). Table 1 .
Figure.
Interaction between ADIPOQ +45T >G polymorphism with (A) blood pressure and (B) plasma total cholesterol level on the odds ratio of coronary artery disease. SBP, systolic blood pressure; DBP, diastolic blood pressure; CI, confidence interval.
Discussion
The present study showed that ADIPOQ +45T >G polymorphism is significantly associated with CAD, independent of known CAD risk factors, in the Chinese population of Taiwan. Furthermore, the protective effect of the G allele at +45T >G polymorphism is modified by BP and plasma cholesterol level, which indicates that there are interactions between genetic factors and traditional risk factors. Consistent with our findings, the G allele of the +45T >G polymorphism has been associated with lower risk of CAD in European 23 and US populations. 24 The protective effect of the G allele was also found in type 2 diabetic patients. 25 However, other studies have reported contradictory results in the general population or in type 2 diabetic patients. [26] [27] [28] [29] [30] [31] [32] The discrepancy might be explained by differences in disease definition and ethnic background. However, given the strong influence of BP and plasma cholesterol level on the genetic effect of the G allele, it is also possible that the prevalence of hypercholesterolemia, hypertension and therapeutic intensity differed in the other studies and interfered with the observed associations. A larger study taking into account the modulating effects of metabolic factors is needed to clarify the association.
The mechanism of how the +45T >G polymorphism of ADIPOQ relates to CAD risk remains to be determined. The G allele at the +45T >G polymorphism has been associated with improved insulin sensitivity and a lower risk of obesity, which may in turn reduce CAD risk. 17, [20] [21] [22] However, the G allele was not significantly associated with BMI or other insulin resistance-related metabolic traits in the control group of the present study. The lack of association may be a result of the homogeneity and limited size of the control group. However, the protective effect of G allele on CAD risk remained significant by adjustment of other metabolic risk factors, indicating an independent effect of ADIPOQ genetic polymorphism on CAD risk.
In support of the findings, adiponectin has been shown to exert direct anti-atherosclerotic effects through mechanisms independent of a systemic insulin-sensitizing effect. Adiponectin suppresses monocyte adhesion to endothelial cells, 33 lipid accumulation in macrophages, foam cell formation, 34 and proliferation and migration of smooth muscle cells. 10, 35 It also modulates the function of endothelial progenitor cells and endothelial cells. 36, 37 The overlapping of cellular pathways by which adiponectin, cholesterol, and BP modulate atherosclerosis also provides a molecular basis for the observed interaction. Recently, a similar interaction has been observed between the 9p21 locus and poor glycemic control on the risk of CAD. 38 These findings demonstrate the complex interactions between genetic factors and traditional CAD risk factors in the development of atherosclerosis.
The +45T >G polymorphism of the human adiponectin gene is a synonymous mutation (GGT → GGG, Gly → Gly) and the way in which this synonymous mutation influences metabolic phenotypes remains to be elucidated. We previously demonstrated that relative adiponectin mRNA levels were higher in in the adipose tissue of carriers with the G allele. 17 The G allele was also associated with significantly higher circulating adiponectin levels. 15, 16 These findings provide a biological basis for the protective effect of this silent polymorphism. The +45T >G polymorphism is located in a linkage disequilibrium (LD) block spanning from the intron 1 to exon 3 of the adiponectin gene. 11, 39 It is also possible that other genetic variants in the LD with the +45T >G polymorphism are causal variants for the association.
Study Limitations
First, the analyses of interactions between +45T >G genotype and BP or plasma cholesterol level were based on post hoc analyses, raising the concern of false-positive results. Second, the plasma adiponectin concentration was not measured and thus the pathophysiologic mechanism underlying the association could not be further dissected. Third, the controls were selected based on the absence of their past CAD history. Therefore, a small proportion of individuals in the control group might have had subclinical atherosclerosis. The control participants were also significantly younger and there were more women than among the CAD participants. However, such misclassification or mismatch, if present, would have biased the results towards the null hypothesis and the significance level would be underestimated. Furthermore, the association of the +45T >G polymorphism with CAD has been further adjusted for age, gender, and other metabolic factors. Fourth, only 1 SNP was genotyped in this study. A more comprehensive coverage of SNPs in ADIPOQ would provide more information regarding the role of ADIPOQ genetic polymorphism in CAD risk. Finally, drug information was missing for some participants, so interference by drug therapy could not be analyzed or excluded. However, as most CAD patients receive anti-hypertensive or lipid-lowering therapy, the present study is actually more applicable to common daily practice.
In conclusion, the present study demonstrates that the +45T >G polymorphism of ADIPOQ is associated with CAD, independent of other known risk factors. The association is strongly modified by BP and plasma cholesterol level. The findings highlight the importance of gene-environment interaction in the development of complex disorders.
